Substatial progress has been made on the elimination of trachoma but challenges in terms of funding and diagnostics remain. Timothy Jesudason reports.

Eli Lilly (NYSE:LLY) reports third-quarter results in about a week, and the split between volume and price matters more than the headline total.

Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

The dividend is probably the reason investors hold Pfizer (PFE), the maker of medicines such as Eliquis and Padcev. The stock ...

Swiss skincare firm Galderma, Brazilian cosmetics group Natura and beauty giant L'Oreal are testing treatments for consumers ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...

For decades, the standard of care for patients with resected stage II and III colon cancer has centred on surgery with consideration of postoperative adjuvant systemic therapy to reduce risk of ...

In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the ...

T-Cell Engager Therapeutics Market to grow from USD 7.2 Bn in 2026 to USD 39.4 Bn by 2036 at a 18.5% CAGR. Get segment, region & competitor insights.

Wall Street rises as healthcare stocks surge and oil prices soften. Discover the latest market trends and sector performance.

This article is a personal record by the author (me) and does not recommend buying or selling any specific stocks. Figures ...

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for ...